Newer hormonal pharmacotherapies for heart failure

References

• Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385:812–824.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
   PubMed Web of Science ®Google Scholar
• Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868–1877.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Aronow WS, Mondal P, et al. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch Med Sci. 2017 Aug;13(5):1207–1216.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768–777.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Kakafika AI, et al. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother. 2007 Apr;8(5):529–535.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006 Oct 21;368(9545):1449–1456.
   PubMed Web of Science ®Google Scholar
• Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001 Jan-Feb;29(1):13–21.
   PubMed Web of Science ®Google Scholar
• Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000 Jul;7(7):493–504.
   PubMedGoogle Scholar
• Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 Mar 1;111(8):1012–1018.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007 Feb;49(2):276–284.
   PubMed Web of Science ®Google Scholar
• Musini VM, Lawrence KA, Fortin PM, et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev. 2017 Apr;5(4):CD007066.
   Google Scholar
• McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May;1(1):17–24.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011 May;32(10):1227–1234.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Abraham WT, Dickstein K, et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012 Apr;14(4):341–343.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013 Mar 20;309(11):1125–1135.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016 Apr 21;374(16):1521–1532.
   PubMed Web of Science ®Google Scholar
• Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9(1):145–149.
   PubMed Web of Science ®Google Scholar
• Schrier RW. Aldosterone ‘escape’ vs ‘breakthrough’. Nat Rev Nephrol. 2010 Feb;6(2):61.
   PubMed Web of Science ®Google Scholar
• Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008;29(17):2171–2179.
   PubMed Web of Science ®Google Scholar
• Furuzono S, Meguro M, Miyauchi S, et al. A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure. Eur J Pharmacol. 2017 Jan;15(795):58–65.
   Google Scholar
• Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10:15–22.
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014 Jul;64(1):69–78.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173–1184.
   PubMed Web of Science ®Google Scholar
• Samuel JL, Delcayre C. Heart failure: aldosterone antagonists are underused by clinicians. Nat Rev Cardiol. 2010;7:125–127.
   PubMed Web of Science ®Google Scholar
• Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, et al. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172–184.
   PubMed Web of Science ®Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug;34(31):2453–2463.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016 Jul 14;37(27):2105–2114.
   PubMed Web of Science ®Google Scholar
• Grune J, Benz V, Brix S, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016 May;67(5):402–411.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol. 2011;57(2):131–140.
   PubMed Web of Science ®Google Scholar
• Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol. 2010;56(3):262–270.
   PubMed Web of Science ®Google Scholar
• Anker SD, Ponikowski P, Mitrovic V, et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015;36(12):715–723.
   PubMed Web of Science ®Google Scholar
• Suwa M, Seino Y, Nomachi Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the `real world’ of therapy. Circ J. 2005;69(3):283–290.
   PubMed Web of Science ®Google Scholar
• Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure. Circ J. 2008;72(11):1787–1793.
   PubMed Web of Science ®Google Scholar
• Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure – A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). J Cardiol. 2013;62:95–101.
   PubMed Web of Science ®Google Scholar
• Kentsch M, Ludwig D, Drummer C, et al. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest. 1992 Oct;22(10):662–669.
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Lüss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150:1239.e1–1239.e8.
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Seferovic P, Simeunovic D, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Euro Heart J. 2006;27:2823–2832.
   PubMed Web of Science ®Google Scholar
• Packer M, O’Connor C, McMurray JJ, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376:1956–1964.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Tariq S, Aronow WS. Advances in chemical pharmacotherapy for managing acute decompensated heart failure. Expert Opin Pharmacother. 2017 Apr;18(5):471–485.
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF).Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002 Mar 27;287(12):1531–1540.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43.
   PubMed Web of Science ®Google Scholar
• Lee CY, Huntley BK, McCormick DJ, et al. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):98–105.
   PubMed Web of Science ®Google Scholar
• Meems LMG, Burnett JC. Innovative therapeutics: designer natriuretic peptides. JACC Basic Transl Sci. 2016;1(7):557–567.
   PubMedGoogle Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor – neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–414.
   PubMed Web of Science ®Google Scholar
• Hegde LG, Yu C, Renner T, et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol. 2011;57:495–504.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–1266, 64.
   PubMed Web of Science ®Google Scholar
• Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
   PubMed Web of Science ®Google Scholar
• Jhund PS, Claggett BL, Voors AA, et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014;7:953–959.
   PubMed Web of Science ®Google Scholar
• Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17:510–517.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Aronow WS, Mondal P, et al. Limitations of sacubitril/valsartan in the management of heart failure. Am J Ther. 2007;24:234–239.
   Google Scholar
• Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54–61.
   PubMed Web of Science ®Google Scholar
• McMurray J, Packer M, Desai AS, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015;36(7):434–439.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Andries G, Biswas M, et al. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Vasc Health Risk Manag. 2017;13:369–382.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Martinez F, Jhund PS, et al. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016;37(41):3167–3174.
   PubMed Web of Science ®Google Scholar
• Simpson J, Jhund PS, Rouleau J, et al. Effect of sacubitril/valsartan compared with enalapril, according to etiology in PARADIGM-HF. Am Coll Cardiol Sci Sessions. 2017 Mar.
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA news release: FDA approves new drug to treat heart failure. [Accessed 2017 June 12]. . Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm
   Google Scholar
• EMA (2015a) Summary of the risk management plan (RMP) for entresto (sacubitril/valsartan). Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/004062/WC500194315.pdf. Accessed 2017 Jun 20.
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23(8):625–651.
   Web of Science ®Google Scholar
• Moe GW, Ezekowitz JA, O’Meara E, et al. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015 Jan;31(1):3–16.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016 Aug;18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9–18.
   PubMed Web of Science ®Google Scholar
• Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006 Jun;69(12):2124–2130.
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417–2423.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators FT. Effects of oral tolvaptan in patients hospitalized for worsening heart failure-The EVEREST Outcome Trial. JAMA. 2007;297(12):1319–1331.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28(8):980–988.
   PubMed Web of Science ®Google Scholar
• Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290(2):F273–F278.
   PubMed Web of Science ®Google Scholar
• Felker G, Mentz RJ, Cole R, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399–1406.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Kiernan M, Chandler A, et al. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017;69(11):1409–1419.
   PubMed Web of Science ®Google Scholar
• Starling RC, Young JB. Tolvaptan in acute heart failure. J Am Coll Cardiol. 2017;69(11):1407–1408.
   PubMedGoogle Scholar
• Ng TMH, Goland S, Elkayam U. Relaxin for the treatment of acute decompensated heart failure: pharmacology, mechanisms of action, and clinical evidence. Cardiol Rev. 2016;24(4):194–204.
   Google Scholar
• Du XJ, Bathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010 Jan;7(1):48–58.
   PubMed Web of Science ®Google Scholar
• Fisher C, Berry C, Blue L, et al. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003;89:879–881.
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009 Apr;15(3):182–190.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009 Apr 25;373(9673):1429–1439.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39.
   PubMed Web of Science ®Google Scholar
• Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013 Jan 15;61(2):196–206.
   PubMed Web of Science ®Google Scholar
• Liu LC, Voors AA, Teerlink JR, et al. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Clin Res Cardiol. 2016 Sep;105(9):727–737.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Voors AA, Ponikowski P, et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail. 2017;19(6):800–809.
   Web of Science ®Google Scholar
• Ertl G, Bauersachs J. Endothelin receptor antagonists in heart failure: current status and future directions. Drugs. 2004;64(10):1029–1040.
   PubMed Web of Science ®Google Scholar
• Nambi P, Clozel M, Feuerstein G. Endothelin and heart failure. Heart Fail Rev. 2001 Dec;6(4):335–340.
   PubMedGoogle Scholar
• Katwa LC. Cardiac myofibroblasts isolated from the site of myocardial infarction express endothelin de novo. Am J Physiol Heart Circ Physiol. 2003;285(3):H1132–H1139.
   PubMed Web of Science ®Google Scholar
• Handoko ML, de Man FS, Vonk-Noordegraaf A. The rise and fall of endothelin receptor antagonists in congestive heart failure. Eur Respir J. 2011;7(3):484–485.
   Google Scholar
• MacCarthy PA, Grocott-Mason R, Prendergast BD, et al. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart studies with an intracoronary ET(A) receptor antagonist. Circulation. 2000 Jan 18;101(2):142–147.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurray JJV, Krum H, et al. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail. 2017 May 5;5:317–326.
   PubMed Web of Science ®Google Scholar
• Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):347–354.
   PubMed Web of Science ®Google Scholar
• Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. J Am Coll Cardiol. 2003;41(2):204–210.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007 Nov 7;298(17):2009–2019.
   PubMed Web of Science ®Google Scholar
• Valero-Munoz M, Li S, Wilson RM, et al. Dual endothelin-a/endothelin-b receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9:e003381.
   PubMed Web of Science ®Google Scholar
• Saccà L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail. 2009 Mar;2(2):151–156.
   PubMed Web of Science ®Google Scholar
• Tsuda T, Takefuji M, Wettschureck N, et al. Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction. J Exp Med. 2017 Jul 3;214(7):1877–1888.
   PubMed Web of Science ®Google Scholar
• Amin A, Chitsazan M, Taghavi S, et al. Effects of triiodothyronine replacement therapy in patients with chronic stable heart failure and low-triiodothyronine syndrome: a randomized, double-blind, placebo-controlled study. ESC Heart Fail. 2015;2:5–11.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Jolly G, Horblitt A, et al. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgrad Med. 2017;27:1–11.
   Google Scholar
• Bundgaard H, Axelsson A, Hartvig Thomsen J, et al. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail. 2017;19:566–575.
   PubMed Web of Science ®Google Scholar